Genovior Biotech Corporation (a dedicated CDMO) signed a Memorandum of Understanding with Clinipace, Inc., a leading global CRO on Aug 01, 2017 to forge a strategic alliance. The aim is to develop a competitive advantage over the current service offering by providing our global clients with an efficient, one-stop solution from CRO to CDMO, satisfying the demand for new drugs/injectable from clinical trials to commercial production.
